Abnormal volume Friday November 30, 2012 analysis reveals money flowing into vs. out of SNSS with a recent peak in share price on October 5, 2012 of $6.85 Since that time technical corrections have occurred with steady accumulation occurring on each indication that an oversold condition existed.
The catalyst: vosaroxin - Sunsesis's most advanced late stage drug in development.
Vosaroxin if successful will be used to treat Acute myeloid leukemia, or AML, an aggressive cancer of the blood.
Wedbush analyst David Nierengarten said he is optimistic that vosaroxin will meet its goals in the trial. He kept an "Outperform" rating on Sunesis shares and raised his price target to $10 per share.
RBC Capital believes that Phase III data for Vosaroxin could surpass expectations, The firm believes the company has a good chance of signing a partnership deal they maintain an Outperform rating on their stock.
Dan Swisher - Chief Executive Officer for Sunesis Pharmaceuticals, Inc, said this: SNS has the cash through 2014, which is beyond several key data milestones. (low chances of dilution before major price increase)
Estimates are are that vosaroxin can likely achieve peak annual sales of $700 million and physicians noted use of vosaroxin likely will extend beyond the refractory AML setting such as first line settings when the patients are at high risk of relapse or have cardiovascular issues.
Favorable outlook was taken on up-sizing of the ongoing phase III study of vosaroxin as it was based on efficacy data trending in the "promising zone" and significantly improves the trials odds of success.
MARKET OUTPERFORM given here price target $20
You will probably agree with this review using some due diligence of your own.